Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Hepatitis C

  Free Subscription


1 Gastroenterology
1 J Hepatol
2 J Viral Hepat
3 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. KIM NJ, Vutien P, Berry K, Ioannou GN, et al
    Hepatocellular carcinoma risk declines but remains high enough for screening in the first 7 years after HCV cure with DAAs in patients with cirrhosis or high FIB-4.
    Gastroenterology. 2022 Jun 28. pii: S0016-5085(22)00681.

    J Hepatol

  2. KARIMI-SARI H, Rezaee-Zavareh MS, Falade-Nwulia O, Lim JK, et al
    Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
    J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02922.

    J Viral Hepat

  3. KUMADA T, Toyoda H, Yasuda S, Ito T, et al
    Original article Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13728.
    PubMed         Abstract available

  4. FORD JS, Hollywood E, Steuble B, Meng Z, et al
    Risk Factors for Hepatitis C Virus Infection at a Large Urban Emergency Department.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13730.
    PubMed         Abstract available

    PLoS One

  5. CHEN YC, Wang HW, Huang YT, Jiang MY, et al
    Association of hepatitis C virus infection status and genotype with kidney disease risk: A population-based cross-sectional study.
    PLoS One. 2022;17:e0271197.
    PubMed         Abstract available

  6. CAIROLI V, De Matteo E, Casciato P, Ameigeiras B, et al
    The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects.
    PLoS One. 2022;17:e0270911.
    PubMed         Abstract available

  7. SHIRAI K, Hikita H, Sakane S, Narumi R, et al
    Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.
    PLoS One. 2022;17:e0271020.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.